Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a
potential treatment of COVID-19. However, meta-analysis data and recommendations are …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

Background: While passive immunotherapy has been considered beneficial for patients with
severe respiratory viral infections, the treatment of COVID-19 cases with convalescent …

Purpose To assess and compare the relative efficacy and safety of anti-SARS-CoV-2
antibody regimens for COVID-19. Methods This systematic review and random-effects …

Background Plasma collected from recovered COVID-19 patients (COVID-19 convalescent
plasma, CCP) was the first antibody-based therapy employed to fight the COVID-19 …

Background Convalescent plasma may reduce mortality in patients with viral respiratory
diseases, and is being investigated as a potential therapy for coronavirus disease 2019 …

The objective of this study was to assess whether convalescent plasma therapy could offer
survival advantages for patients with novel coronavirus disease 2019 (COVID-19). An …

Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …